Subcutaneous alemtuzumab in patients with refractory/relapsed B-CLL after a fludarabine-based regimen.

被引：0

作者：

Bezares, R.

Stemmelin, G.

Argentieri, D.

Lanari, E.

Guy-Garay, E.

Campestri, R.

Bartomioli, M.

Garcia, J.

Giralt, S.

Milone, G.

机构：

[1] Hosp Gen Agudos, Buenos Aires, DF, Argentina

[2] Hosp Britan, Buenos Aires, DF, Argentina

[3] Sanatorio Mitre, Buenos Aires, DF, Argentina

[4] Ctr Med Corrientes, Buenos Aires, DF, Argentina

[5] CEMIC, Buenos Aires, DF, Argentina

[6] Hosp Pena Bahia Blanca, Buenos Aires, DF, Argentina

[7] Hosp Privado Cordova, Cordova, Argentina

[8] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Fundaleu, Buenos Aires, DF, Argentina

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：360S / 360S

页数：1

共 50 条

[1] Subcutaneous alemtuzumab in patients with refractory/relapsed B-cell CLL after a fludarabine-based regimen. An interim analysis.
Bezares, R. Fernando
Stemmelin, German
Argentieri, Daniel
Lanari, Emilio
Guy-Garay, Efrain
Campestri, Reinaldo
Bartomioli, Miguel
Garcia, Juan Jose
Giralt, Sergio
Milone, Gustav
BLOOD, 2006, 108 (11) : 805A - 805A
[2] FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A.
Melchardt, T.
Pleyer, L.
Tinhofer, I.
Lang, A.
Keil, F.
Thaler, J.
Gunsilius, E.
Fridrik, M.
Greil, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 140 - 140
[3] EBV reactivation in patients with lymphoproliferative diseases receiving a fludarabine-based regimen.
Lazzarino, M
Orlandi, E
Baldanti, F
Pagnucco, G
Astori, C
Arcaini, L
Sarasini, A
Gerna, G
Bernasconi, C
BLOOD, 1998, 92 (10) : 623A - 623A
[4] Infectious morbidity after a fludarabine-based reduced dose-conditioning regimen.
Magalhaes-Silverma, M
Carter, T
Hohl, R
Lee, CK
Schlueter, A
Gingrich, R
BLOOD, 2002, 100 (11) : 443B - 444B
[5] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL
Wierda, W
Faderl, S
O'Brien, S
Cortes, J
Ferrajoli, A
Giles, F
Andreff, M
Koller, C
Kantarjian, H
Keating, M
BLOOD, 2004, 104 (11) : 101A - 101A
[6] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
Wierda, W
O'Brien, S
Ferrajoli, A
Faderl, S
Kornblau, SM
Andreef, M
Koller, C
Garcia-Manero, G
Thomas, D
Kantarjian, H
Keating, M
BLOOD, 2003, 102 (11) : 360B - 360B
[7] Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL
Fiegl, Michael
Falkner, Florian
Falkner, Andreas
Zojer, Niklas
Fridrik, Michael
Hopfinger, Georg
Stauder, Reinhard
Gunsilius, Ebehard
Kantner, Johanna
Erdel, Martin
Tinhofer, Inge
Gastl, Guenther
Greil, Richard
BLOOD, 2007, 110 (11) : 252B - 252B
[8] Outpatient-based therapy with oral fludarabine and alemtuzumab for Asian patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Hwang, William
Dearden, C.
Loh, S. M.
Linn, Y. C.
Tien, S. L.
Teoh, G.
Lim, L. F.
Liew, P. X.
How, G. F.
Heng, K. K.
Goh, Y. T.
Lee, L. H.
BLOOD, 2006, 108 (11) : 336B - 337B
[9] Pharmacokinetics and response to treatment using a combination of fludarabine and alemtuzumab (FluCam) in patients with relapsed/refractory CLL.
Elter, T.
Kilp, J.
Piironen, T.
Borchmann, P.
Schulz, H.
Bohlius, J.
Hallek, Michael J.
Engert, Andreas
BLOOD, 2006, 108 (11) : 336B - 336B
[10] Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG)
Stilgenbauer, Stephan
Winkler, Dirk
Buehler, Andreas
Zenz, Thorsten
Groner, Sija
Busch, Raymonde
Hensel, Manfred
Duehrsen, Uhich
Finke, Juergen
Dreger, Peter
Jaeger, Ulrich
Lengfelder, Eva
Truemper, Lorenz
Soeling, Ulrike
Schlag, Rudolf
Hallek, Michael
Doehner, Hartmut
BLOOD, 2007, 110 (11) : 918A - 918A

← 1 2 3 4 5 →